|
|
|
02.04.25 - 08:42
|
Immunovia publishes the Annual Report for 2024 (PR Newswire)
|
|
|
LUND, Sweden, April 2, 2025 /PRNewswire/ -- Immunovia AB (publ) today announced that the Annual Report for 2024 has been published. The annual report can be downloaded in pdf format and is available on Immunovia's website. For more information, please contact: Jeff Borcherding CEO and......
|
|
|
02.04.25 - 08:36
|
Immunovia publishes the Annual Report for 2024 (Cision)
|
|
|
LUND, SWEDEN – Immunovia AB (publ) today announced that the Annual Report for 2024 has been published.
The annual report can be downloaded in pdf format and is available on Immunovia's website.
For more information, please contact:
Jeff Borcherding
CEO and President
jeff.borcherding@immunovia.com
Immunovia in brief
Immunovia AB (IMMNOV: Nasdaq Stockholm), is a diagnostic company whose mission is to increase survival rates for patients with pancreatic cancer through early detection. Immunovia is focused on the development and commercialization of...
|
|
|
01.04.25 - 08:45
|
The exercise period for warrants series TO 3 begins today (PR Newswire)
|
|
|
LUND, Sweden, April 1, 2025 /PRNewswire/ -- Today, 1 April 2025, the exercise period for warrants series TO 3 in Immunovia AB (publ) ("Immunovia" or the "Company") (the "Warrant Programme") begins. The exercise period runs until 15 April 2025. Summarized terms for the warrants of series......
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25.02.25 - 08:51
|
Immunovia Publishes Full Year Report for 2024 (PR Newswire)
|
|
|
LUND, Sweden, Feb. 25, 2025 /PRNewswire/ -- October-December 2024 Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155). Net earnings were 3,1 MSEK (-49,0) as a result of unrealized exchange rate effects due to a higher dollar rate on the transactions to......
|
|
|
25.02.25 - 08:36
|
Immunovia Publishes Full Year Report for 2024 (Cision)
|
|
|
October-December 2024
· Net sales, which for the quarter only included royalties, amounted to 455 KSEK (155).
· Net earnings were 3,1 MSEK (-49,0) as a result of unrealized exchange rate effects due to a higher dollar rate on the transactions to finance operations in Immunovia Inc.
· Operating losses were -30,1 MSEK (-23,4).
· Earnings per share before and after dilution were 0.02 SEK (-1,08).
· Cash flow from operating activities amounted to -28,3 MSEK (-28,5).
· Cash and cash equivalents at end of period equaled 25,3 MSEK (76,8).
· On October 2, the company...
|
|
|
|
|
31.01.25 - 11:36
|
Change in number of shares and votes in Immunovia AB (publ) (PR Newswire)
|
|
|
LUND, Sweden, Jan. 31, 2025 /PRNewswire/ -- During January 2025, the registered number of shares and votes in Immunovia AB (publ) ("Immunovia") has increased due exercise of warrants of series TO 2. As of 31 January 2025, the registered number of shares and votes in Immunovia amounts to......
|
|
|
|
|
08.01.25 - 13:57
|
Immunovia AB (Publ) presents Nomination Committee (PR Newswire)
|
|
|
LUND, Sweden, Jan. 8, 2025 /PRNewswire/ -- Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the appointment of the Company's Nomination Committee. According to the instructions for the Nomination Committee of Immunovia AB (Publ), the......
|
|
|
|
|
02.01.25 - 08:30
|
The exercise period for warrants of series TO 2 beings today (Cision)
|
|
|
Immunovia AB (publ) (“Immunovia” or the “Company”) hereby announces that today, 2 January 2025, the exercise period for warrants of series TO 2 in Immunovia AB (publ) (“Immunovia” or the “Company”) (the “Warrant Programme”) begins. The exercise period runs until 16 January 2025.
Summarized terms for the warrants of series TO 2
· Structure: One (1) warrant series TO 2 entitles the holder to subscribe for one (1) new share in the Company.
· Exercise period: 2 January 2025 – 16 January 2025.
· Subscription price: SEK 0.46 per share.
· Issue volume: 124,423,978 warrants of...
|
|
|
|
|
27.12.24 - 23:48
|
Immunovia announces determined exercise price for warrants series TO 2 and conditionally securing 65% of the warrant programme (Cision)
|
|
|
Immunovia AB (publ) (“Immunovia” or the “Company”) hereby announces that the exercise price for warrants series TO 2 (the “warrants”) has been determined to SEK 0.46. The exercise period for the warrants commences on 2 January 2025 and runs up to and including 16 January 2025. The last day for trading in the warrants is 14 January 2025. In addition to the subscription intentions from the Company's CEO and board members, which were announced on 18 December 2024, encompassing approximately SEK 0.8 million, Immunovia has received a subscription commitment of approximately SEK 0.1 million and...
|
|
|
20.12.24 - 11:48
|
Immunovia discovery study published in top protein research journal (Cision)
|
|
|
LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announced the peer-reviewed publication of the discovery study conducted by Immunovia to identify protein biomarkers for its next-generation pancreatic cancer test in the Journal of Proteome Research. The study is the largest and most comprehensive pancreatic cancer proteomics study done to date.
The discovery study identified 41 promising protein biomarkers that were shown to strongly correlate with the presence of pancreatic ductal adenocarcinoma (PDAC), the most common form of...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
